UnitedHealthcare Provides Commercial Coverage for FoundationOne®CDx a...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 27, 2024

Badger Meter Declares Regular Quarterly Dividend • Suzano 2023 annual report on Form 20-F • The Sallie Mae Fund Grants $75,000 to DC College Access Program to Support Higher Education Access and Completion • Whitman-Walker Institute Applauds the Biden-Harris Administration for Finalizing Robust Affordable Care Act Nondiscrimination Pr • Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions • Latin America CDC a Must, say Public Health Leaders and AHF • Brothers to Host Grand Opening Event for JDog Junk Removal & Hauling Business on April 28th • Books-A-Million Launches Its 22nd Coffee for the Troops Donation Campaign • Greenberg Traurig is a Finalist for Legal Media Group's 2024 Women in Business Law EMEA Awards • Toro Taxes, the Leading Latino Tax Franchise selects Trez, to power Payroll solutions • Broadstone Net Lease Issues 2023 Sustainability Report • US Marine Corps Veteran to Celebrate Grand Opening of JDog Junk Removal & Hauling in Findlay on May 4th • Chase Opens Innovative Branch in Bronx’s Grand Concourse Neighborhood • Carbon Removal and Mariculture Legislation Moves Forward in California Assembly • Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch • Levy Konigsberg Files Lawsuits on Behalf of 25 Men Who Allege They Were Sexually Abused as Juveniles Across Four New Jersey Juve • L.A. Care and Blue Shield of California Promise Health Plans Celebrate New Community Resource Center in West Los Angeles, Highli • CareTrust REIT Sets First Quarter Earnings Call for Friday, May 3, 2024 • 29 London Partners With US Media Company Bobi Media to Strengthen Market Offering • Getting Tattooed with Gay History

UnitedHealthcare Provides Commercial Coverage for FoundationOne®CDx and FoundationOne®Liquid CDx in Multiple Companion D

CAMBRIDGE, Mass. , February 09 /Businesswire/ - Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, announced today that UnitedHealthcare commercial plans will cover FoundationOne®CDx as a companion diagnostic in all solid tumors for patients with unresectable or metastatic cancer being considered for treatment with an immune checkpoint inhibitor and meeting coverage criteria. Additionally, FoundationOne®Liquid CDx will be covered as a companion diagnostic for patients with advanced breast cancer, metastatic non-small cell lung cancer (NSCLC), recurrent ovarian cancer and metastatic castrate-resistant prostate cancer (mCRPC) meeting coverage criteria. Coverage is effective April 1, 2023. FoundationOne CDx, a tissue-based comprehensive genomic profiling (CGP) test, and FoundationOne Liquid CDx, a CGP liquid biopsy test, are used to identify patients who may benefit from treatment with specific FDA-approved targeted therapies.

“We believe patients and their physicians deserve the highest quality genomic testing to make informed decisions about personalized treatment,” said Foundation Medicine Chief Executive Officer Brian Alexander, M.D., M.P.H. “UnitedHealthcare’s coverage decision will improve patient access to molecular profiling and enable better outcomes for patients.”

UnitedHealthcare’s planned coverage of FoundationOne CDx and FoundationOne Liquid CDx is in addition to coverage that Foundation Medicine already has for these tests from other national and regional commercial providers, as well as by Medicare and Medicare Advantage plans.

About Foundation Medicine: Your Essential Partner in Cancer Care

Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on www.FoundationMedicine.com and follow us on Twitter and LinkedIn.

About FoundationOne CDx

FoundationOne CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit www.F1CDxLabel.com.

About FoundationOne Liquid CDx

FoundationOne Liquid CDx is a qualitative next generation sequencing based in vitro diagnostic test for prescription use only that uses targeted high throughput hybridization-based capture technology to analyze 324 genes utilizing circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood of advanced cancer patients. The test is FDA-approved to report short variants in over 300 genes and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients who are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.

Source: Foundation Medicine